

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: COLLINS et al.	)	Examiner: Wang, Chang Yu
	:	
Application No.: 10/806,611	)	Group Art Unit: 1649
	:	
Filed: March 22, 2004	)	Confirmation No.: 2470
	:	
For: TREATING IMMUNOLOGICAL	)	Customer No.: 45743
DISORDERS USING AGONISTS OF:	:	
INTERLEUKIN-21 /	)	May 14, 2007
INTERLEUKIN-21 RECEPTOR	:	
	)	

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed documents are also enclosed.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

We also enclose a check for the required fee of \$180.00 to cover the Information Disclosure Statement under 37 C.F.R. 1.97(c)(2).

05/21/2007 MWOLDGE1 00000013 10006611

01 FC:1006

100.00 0P


Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Joseph P. Pieroni", written over a horizontal line.

Joseph P. Pieroni  
Attorney for Applicants  
Registration No.:53,469

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3800  
Facsimile: (212) 218-2200

FORM PTO 1449 (modified)		ATTY DOCKET NO. <b>01997.043200</b>	APPLICATION NO. <b>10/806,611</b>
 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		APPLICANT <b>COLLINS et al.</b>	
		FILING DATE <b>March 22, 2004</b>	GROUP <b>1649</b>
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
		<b>"Sample GenBank Record instructions," printed February 15, 2007, 17 pages.</b>	
		<b>"RefSeq instructions," printed March 29, 2007, 7 pages.</b>	
		<b>GenBank Accession Number XP_011082, "Interleukin-21 [Homo sapiens] protein," NCBI Annotation Project (2001), submitted October 11, 2001, printed March 29, 2007, 2 pages.</b>	
		<b>GenBank Accession Number XM_011082, "Interleukin-21 [Homo sapiens] mRNA," NCBI Annotation Project (2001), submitted October 11, 2001, printed April 4, 2007, 2 pages.</b>	
		<b>Merriam-Webster Online Dictionary definition, "Definition of agonist," printed March 2, 2007, 1 page.</b>	
		<b>Davis et al. (1994), §20-3: "Site-directed mutagenesis," Basic Methods in Molecular Biology (pp. 738-744), 2<sup>nd</sup> edition, Appleton &amp; Lange, CT.</b>	
		<b>Steinman and Zamvil (2006) "How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multiple Sclerosis," Ann. Neurol. 60:12-21.</b>	
		<b>Smith et al. (1999) "IL-10 as a mediator in the HPA axis and brain," J. Neuroimmunol. 100:140-48.</b>	
		<b>Bjartmar et al. (1999) "Axonal pathology in myelin disorders," J. Neurocytol. 28:383-95.</b>	
		<b>Brandt et al. (2001) "Generation of Antagonists by Amino Acid Replacement in the D-helix of Human IL-21," J. Leukoc. Biol. (Suppl.), p. 46, 1 page (with enlargement).</b>	
		<b>Reichert and Pavlou (2004) "Monoclonal antibodies market," Nat. Rev. Drug Discovery 3:383-84.</b>	
		<b>GenBank Accession Number NP_068554, "Interleukin-21 [Mus Musculus] protein," Parrish-Novak et al. (2000), printed April 13, 2007, 3 pages.</b>	
		<b>Blast 2 Sequences Results comparing mature human and mature mouse IL-21 (SEQ ID NOs: 2 and 4), entitled "Amino Acid Sequence Alignment of Mature Human and Mouse IL-21," printed April 4, 2007, 2 pages.</b>	
EXAMINER		DATE CONSIDERED	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1